Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 11:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 816 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Butyrate Clear all
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

NCT06425302
View directory record Official record
Conditions
Lymphoma, Follicular
Interventions
Golcadomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Bendamustine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 26, 2026, 11:43 PM EDT
Completed Phase 2 Interventional Results available

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

NCT00357500
View directory record Official record
Conditions
Central Nervous System Tumor, Pediatric, Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
celecoxib, cyclophosphamide, etoposide, fenofibrate, thalidomide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 21 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
10
States / cities
Hartford, Connecticut • Miami, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 26, 2026, 11:43 PM EDT
Completed Phase 4 Interventional Results available

A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™

NCT00891293
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
32
States / cities
Spring Valley, California • Washington D.C., District of Columbia • Coral Gables, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Oct 26, 2026, 11:43 PM EDT
Recruiting Phase 3 Interventional

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

NCT06846671
View directory record Official record
Conditions
CLL, Chronic Lymphocytic Leukemia
Interventions
Tacabrutideg, Bendamustine, Idelalisib, Rituximab, Venetoclax
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
29
States / cities
Jonesboro, Arkansas • Los Angeles, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 26, 2026, 11:43 PM EDT
Completed Phase 2 Interventional

SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)

NCT00076349
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
bendamustine and rituximab
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
25
States / cities
Anchorage, Alaska • Concord, California • La Verne, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 26, 2026, 11:43 PM EDT
Terminated Phase 4 Interventional Results available

Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia

NCT01603394
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
pregabalin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Leesburg, Florida • Lexington, Kentucky • Raleigh, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Oct 26, 2026, 11:43 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain

NCT03407430
View directory record Official record
Conditions
Breast Cancer, Lymphoma, Pain
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 26, 2026, 11:43 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma

NCT00636792
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
VELCADE, Bendamustine, Rituximab
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bismarck, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 26, 2026, 11:43 PM EDT
Completed Phase 2 Interventional Results available

Gabapentin Treatment of Cannabis Dependence

NCT00395044
View directory record Official record
Conditions
Cannabis Dependence
Interventions
Placebo, Gabapentin
Drug
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 26, 2026, 11:43 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Impact of Preoperative Opioid-free Multimodal Analgesia on Time to Trial of Void in Ambulatory Urogynecologic Surgeries

NCT06379425
View directory record Official record
Conditions
Pain, Postoperative, Postoperative Pain, Acute
Interventions
Acetaminophen, Celecoxib, Gabapentin
Drug
Lead sponsor
Northwell Health
Other
Eligibility
Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bay Shore, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 26, 2026, 11:43 PM EDT
Not listed Phase 4 Interventional

Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy

NCT01770964
View directory record Official record
Conditions
Diabetes Mellitus, Painful Distal Symmetric Sensorimotor Polyneuropathy
Interventions
Pregabalin, placebo, Training Type A, Training Type B
Drug · Behavioral
Lead sponsor
Analgesic Solutions
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Brighton, Massachusetts • Watertown, Massachusetts • Johnson City, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 26, 2026, 11:43 PM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

NCT04745832
View directory record Official record
Conditions
Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma
Interventions
Zandelisib, Rituximab, Bendamustine, CHOP
Drug
Lead sponsor
MEI Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
14
States / cities
Tucson, Arizona • Fountain Valley, California • Long Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 26, 2026, 11:43 PM EDT
Completed Phase 2 Interventional Results available

Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

NCT01286272
View directory record Official record
Conditions
Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions
Bendamustine Hydrochloride, Bortezomib, Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Ofatumumab, Positron Emission Tomography with Radiolabeled Targeting Agent
Drug · Radiation · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
96
States / cities
La Jolla, California • St. Helena, California • Middletown, Connecticut + 70 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 26, 2026, 11:43 PM EDT
Completed Phase 2 Interventional Results available

Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

NCT03609593
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Bendamustine, Venetoclax, Rituximab
Drug
Lead sponsor
Nicole Lamanna
Other
Eligibility
18 Years to 99 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 26, 2026, 11:43 PM EDT
Completed Phase 1 Interventional

Drug Discrimination in Methadone-Maintained Humans Study 1

NCT00593463
View directory record Official record
Conditions
Drug Dependence
Interventions
Cycloserine, Diltiazem, Gabapentin, Isradipine, Naloxone, Nifedipine, Placebo, Saline, Verapamil
Drug · Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2011 · Synced Oct 26, 2026, 11:43 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures

NCT00448916
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Month to 16 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
16
States / cities
Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 26, 2026, 11:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ButyraGen™, Short Chain Fatty Acids and Gut Microbiome

NCT05601635
View directory record Official record
Conditions
Healthy
Interventions
ButyraGen™
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 26, 2026, 11:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study to Determine the Effect of Synbiotics in Patients With Pre-diabetes

NCT04428606
View directory record Official record
Conditions
PreDiabetes
Interventions
Metabolic Rheostat, Butyrate Ultra, Placebo
Dietary Supplement
Lead sponsor
Zhaoping Li
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Oct 26, 2026, 11:43 PM EDT
Terminated Phase 3 Interventional

Gabapentin for the Treatment of Neuroleptic-Induced Tremor

NCT00533455
View directory record Official record
Conditions
Neuroleptic-Induced Tremor
Interventions
Gabapentin
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 24, 2007 · Synced Oct 26, 2026, 11:43 PM EDT
Completed Phase 3 Interventional Results available

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

NCT03345914
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Matching Placebo, Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 26, 2026, 11:43 PM EDT
Completed Phase 4 Interventional Results available

Fenofibrate in Type 2 Diabetes

NCT03829514
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Fenofibrate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 26, 2026, 11:43 PM EDT
Completed Phase 2 Interventional Results available

Gabapentin for Bipolar & Cannabis Use Disorders

NCT03334721
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder, Cannabis Use Disorder, Substance Use Disorders
Interventions
Gabapentin, Placebo Oral Capsule
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 26, 2026, 11:43 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Pain Associated With Fibromyalgia

NCT02146430
View directory record Official record
Conditions
Pain Associated With Fibromyalgia
Interventions
DS-5565, Pregabalin, Placebo tablet, Placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
92
States / cities
Glendale, Arizona • Phoenix, Arizona • Anaheim, California + 89 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 26, 2026, 11:43 PM EDT
Completed Phase 1 Interventional

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

NCT01871675
View directory record Official record
Conditions
Lymphoma, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, T-cell Lymphoma
Interventions
IPI-145, Rituximab, Bendamustine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 26, 2026, 11:43 PM EDT